News Detail
Boston, 11 Dec 2024: A novel, fixed-duration drug combination — consisting of a second-generation BTK inhibitor, called acalabrutinib, plus a BCL-2 inhibitor (venetoclax), with or without a third blood cancer drug — shows deep and durable responses in patients with ch......
View Details
Source : Dana-Farber Cancer Institute
Blood
Blood Cancer
Cancer
Children
Chronic
Chronic Lymphocytic Leukemia
Efficacy
Hematology
Hospital
Leukemia
Research
Rituximab
Related News
- Major drug haul seized in Ferozepur, two case registered (22-01-2025)
- NCB, Police and Drug Controller should take action on online sale of banned medicines: MP HC (22-01-2025)
- Cyrus Poonawalla honoured with Dr K Anji Reddy Memorial Fellowship by ICT, Mumbai (22-01-2025)
- Neutral Substances must be Considered Alongside Narcotics to Determine Quantity Classification: Chhattisgarh HC (22-01-2025)
- Manipur woman held for possession of 8,000 Tapentadol tablets in Chennai (22-01-2025)
- PIL questioning quality of Anti-Rabies Vaccine disposed of by SC (22-01-2025)
- NCB seizes drugs worth more than 14 lakhs in Jaipur, One arrested (21-01-2025)
- Trump withdraws US from WHO (21-01-2025)
- Telangana Officials Raid Illegal De-Addiction Center in Hanumakonda (21-01-2025)
- Major pharmacy benefit managers found by US FTC to have inflated drug prices for a $7.3 billion gain (21-01-2025)